0. DOCID:4439 SCORE: 0.000866040698845837
DOCNO: 7031600
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: therapy
AUTHOR: J P Sculier JP
AUTHOR: J Klastersky J
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
JOURNALTITLE: La Nouvelle presse m├ędicale.
COUNTRY: FRANCE
TITLE: [Hypothermia: a new approach to the treatment of cancer (author's transl)]
PUBDATE: 19811101
Hyperthermia has been known since the last century to be effective against cancer, but it has only developed into a new therapeutic method during the past 20 years. The authors review the theoretical and experimental backgrounds of fever therapy and discuss its local and general applications currently under study, including possible synergistic effects with radiotherapy and/or chemotherapy. Particular attention is paid to systemic hyperthermia.


1. DOCID:5755 SCORE: 0.000841127551683544
DOCNO: 6969375
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Colonoscopy
QUALIFIER: diagnosis
QUALIFIER: utilization
AUTHOR: W H Isbister WH
PUBTYPE: Journal Article
JOURNALTITLE: The New Zealand medical journal.
COUNTRY: NEW ZEALAND
TITLE: Flexible fibreoptic sigmoidoscopy--an alternative to colonoscopy?
PUBDATE: 19801001
The results of 166 colonoscopic examinations are reported with particular reference to site and nature of the lesion identified. One hundred and fifty-five polyps and 13 colorectal cancers were found, 62 polyps and five cancers being beyond 50 cm from the anal verge. It is suggested that the number of lesions beyond the reach of a flexible fibreoptic sigmoidoscope would be unacceptably high and that there can be no justification for the purchase of such an instrument as an alternative to a full length colonoscope. Whilst the fibreoptic instrument does have advantages as a sigmoidoscope its cost will preclude its widespread use in New Zealand at the present time.


2. DOCID:6038 SCORE: 0.000838802336043531
DOCNO: 646710
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
QUALIFIER: therapy
AUTHOR: H R Konrad HR
AUTHOR: R F Canalis RF
AUTHOR: T C Calcaterra TC
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Archives of otolaryngology (Chicago, Ill. : 1960)
COUNTRY: UNITED STATES
TITLE: Epidermoid carcinoma of the palate.
PUBDATE: 19780401
A retrospective study was made of 80 cases of epidermoid carcinoma of the palate that were treated at the UCLA Center for the Health Sciences between 1955 and 1977. Tumor size larger than 3 cm, extension to neighboring structures, and contralateral, bilateral, and "fixed" lymph node metastases substantially decreased survival. The presence of ipsilateral nodes and the modality of treatment used (surgery or irradiation) did not appear to affect the outcome. Three-year cure rates for all cases was 40%. Ninety percent of recurrences took place during the first two years after treatment, and additional cancers developed in the upper aerodigestive tract of 20% of the patients.


3. DOCID:6303 SCORE: 0.000829625976638676
DOCNO: 736648
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
AUTHOR: T W Buchholtz TW
AUTHOR: C E Welch CE
AUTHOR: R A Malt RA
PUBTYPE: Journal Article
JOURNALTITLE: Annals of surgery.
COUNTRY: UNITED STATES
TITLE: Clinical correlates of resectability and survival in gastric carcinoma.
PUBDATE: 19781201
The course of 201 patients with carcinoma of the stomach treated from 1962 through 1966 was followed with 97% determinacy for 10 years. The actual five year survival rate was 11%; the ten year rate was 7%. The mean duration of survival was 5.8 +/- 2.7 (S.D.) months. These results were similar to those reported for the period 1922-1926. Survival was strongly correlated with the surgeon's assessment after exploration. All patients alive after five years had operations thought to be curative, usually partial gastrectomies; the survival rate of this group was 24%. Gastroenterostomy was ineffectual palliation. Better results will require nonsurgical adjuncts, since the correlates of survival are those of minimally invasive cancer.


4. DOCID:6456 SCORE: 0.00080082028983863
DOCNO: 531538
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
AUTHOR: H Rostad H
AUTHOR: J R Vale JR
AUTHOR: I Nesthus I
PUBTYPE: Journal Article
JOURNALTITLE: Scandinavian journal of respiratory diseases.
COUNTRY: DENMARK
TITLE: Lung cancer. Symptoms, signs and diagnostic criteria.
PUBDATE: 19790801
A consecutive hospital series of 1 053 patients treated for lung cancer during the period 1962 through 1971 has been studied. Clinical symptoms were present more often in men than in women and in 42% symptoms had been noted more than 6 months prior to the diagnosis. Peripheral tumours gave less symptoms than central ones. Although in 22% of the patients the tumour was discovered on a chest film in the absence of relevant symptoms, 12% only had been detected by regular mass X-ray screening. More than 40% of the peripherally located tumours were clinically silent. Squamous cell and anaplastic small cell cancers were predominantly centrally located (80 and 90%, respectively) against 65% and 74% for adenocarcinomas and undifferentiated large cell tumours.


5. DOCID:7529 SCORE: 0.000559001759309032
DOCNO: 93183
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: administration & dosage
QUALIFIER: drug therapy
QUALIFIER: analogs & derivatives
QUALIFIER: drug therapy
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: P J Selby PJ
AUTHOR: R L Powles RL
AUTHOR: B Janeson B
AUTHOR: H E Kay HE
AUTHOR: J G Watson JG
AUTHOR: R Thornton R
AUTHOR: G Morgenstern G
AUTHOR: H M Clink HM
AUTHOR: T J McElwain TJ
AUTHOR: H G Prentice HG
AUTHOR: R Corringharn R
AUTHOR: M G Ross MG
AUTHOR: A V Hoffbrand AV
AUTHOR: D Brigden D
PUBTYPE: Journal Article
JOURNALTITLE: Lancet.
COUNTRY: ENGLAND
TITLE: Parenteral acyclovir therapy for herpesvirus infections in man.
PUBDATE: 19791201
Acyclovir is a new antiviral agent which is highly active against herpesviruses in vitro and in laboratory animals. Twenty-three cancer patients with cutaneous and/or systemic herpes zoster or herpes simplex infections were treated with parenteral acyclovir. All had received previous specific treatment for their malignant disease and ten had undergone bone-marrow transplantation. The drug seemed to arrest the progress of the infections and was most effective when given early. Although two patients showed transient increases in blood-urea, possibly the result of acyclovir, the drug was remarkably non-toxic in the doses used.


6. DOCID:4845 SCORE: 0.000558829525268081
DOCNO: 255161
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: therapeutic use
QUALIFIER: radiotherapy
AUTHOR: A Osaka A
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of microwave power.
COUNTRY: CANADA
TITLE: Use of microwave radiation in surgery and cancer therapy.
PUBDATE: 19780601
In considering the therapy of cancer, the author has been interested in the internal dielectric heating property of microwaves and applied their capacity of rapid protein coagulation to medical treatment. With the purpose of utilizing this phenomenon for the resection of fragile parenchymatous organs, the experiment was conducted on rabbit livers, which were irradiated with microwaves for about 3 min. The effect of this phenomenon on cancer cells was also observed. Malignant tumors induced in rats were exposed to microwave radiation for 2 min.


7. DOCID:7224 SCORE: 0.00055879761447627
DOCNO: 86616
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: blood
QUALIFIER: analysis
AUTHOR: R A Bunning RA
AUTHOR: S L Haworth SL
AUTHOR: E H Cooper EH
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of urology.
COUNTRY: UNITED STATES
TITLE: Serum beta-2-microglobulin levels in urological cancer.
PUBDATE: 19790501
Serum beta-2-microglobulin levels were measured in patients with renal, vesical and prostatic cancer. Measurements were made only on samples with a serum creatinine less than or equal to 105 mumol./l. to eliminate the possibility of elevated beta-2-microglobulin being a result of impaired renal function. This criterion eliminated 28 to 50 per cent of the patients with bladder cancer and 73 per cent of those who had undergone nephrectomy for renal carcinoma, which, obviously, limits the value of beta-2-microglobulin measurement for the surveillance in these cancers. Beta-2-microglobulin values in patients with prostatic cancer were seldom increased to more than 3.0 mg./l. In bladder cancer patients with normal serum creatinine the frequency of an elevated serum beta-2-microglobulin increased with the increase in tumor stage.


8. DOCID:7704 SCORE: 0.000558475253812593
DOCNO: 7229433
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiation effects
QUALIFIER: radiation effects
QUALIFIER: etiology
QUALIFIER: adverse effects
AUTHOR: I Willis I
AUTHOR: J M Menter JM
AUTHOR: H J Whyte HJ
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of investigative dermatology.
COUNTRY: UNITED STATES
TITLE: The rapid induction of cancers in the hairless mouse utilizing the principle of photoaugmentation.
PUBDATE: 19810501
We report a method for rapidly inducing cancer in the hairless mouse utilizing regimen in which an exposure to highly erythemogenic, but otherwise clinically noninjurious, dose of broad spectrum (290-400 nm) ultraviolet light is increased by 20% every 6th day. Clinical and histological observations reveal the presence of squamous cell cancer after as little as 18 days of irradiation. The rate of cancer induction is enhanced by the 320-400 nm component and this enhancement is shown to be a photoaugmentative effect. The results support the idea that stratum corneum and/or malpighian layer thickening produced in early stages of tumor induction tends to protect against the detrimental effects of UV radiation. Strict monitoring of both the spectral distribution and output of the radiation source is imperative for reproducible rates of tumor induction.


9. DOCID:5918 SCORE: 0.000557241498221573
DOCNO: 7287476
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: J E Altwein JE
PUBTYPE: Journal Article
JOURNALTITLE: Helvetica chirurgica acta.
COUNTRY: SWITZERLAND
TITLE: [Current aspects of hormonal therapy in prostate cancer]
PUBDATE: 19810801
The following endocrine treatment modalities have been used in advanced prostatic carcinoma: 1. orchiectomy plus estrogens; 2. primary orchiectomy with delayed estrogen employment; 3. initial estrogen therapy with delayed orchiectomy; 4. initial cyproterone acetate or medroxyprogesterone acetate; 5. a combination treatment: estramustine phosphate, cyproterone acetate or estrogens plus bromocriptine. The application of phase-III studies permits the subsequent conclusions: Simultaneous orchiectomy is to no advantage (exception: urinary stasis). Cyproterone acetate does neither yield better nor worse results regarding survival than estrogen alone, but has fewer side effects. Estrogens and cyproterone acetate produce a rise of serum prolactin justifying the use of bromocriptine (or lisuride). Estramustine phosphate should be reserved for relapsing prostatic cancer.


10. DOCID:6614 SCORE: 0.000556383305716214
DOCNO: 361145
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Hyperbaric Oxygenation
QUALIFIER: radiotherapy
AUTHOR: S Dische S
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
JOURNALTITLE: The British journal of radiology.
COUNTRY: ENGLAND
TITLE: Hyperbaric oxygen: the Medical Research Council trials and their clinical significance.
PUBDATE: 19781101
The clinical trials of the use of hyperbaric oxygen in radiotherapy conducted by the Medical Research Council's working party have shown that local cure and survival can be improved in head and neck and cervical cancer. Evidence for benefit has been presented in carcinoma of bronchus, but none has so far been found in carcinoma of the bladder. Although hyperbaric oxygen has produced increased effect upon normal tissues as well as upon tumour, a real improvement in therapeutic ratio appears to be present. The future use of hyperbaric oxygen in radiotherapy will depend upon a comparison of effectiveness with other methods now being tested to improve radiotherapy. The trials have yielded much fundamental and clinical data of general relevance in the radiotherapy of malignant disease.


11. DOCID:6960 SCORE: 0.000554074844345473
DOCNO: 460744
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: epidemiology
QUALIFIER: epidemiology
AUTHOR: N A Nealon NA
AUTHOR: W M Christopherson WM
PUBTYPE: Journal Article
JOURNALTITLE: Obstetrics and gynecology.
COUNTRY: UNITED STATES
TITLE: Cervix cancer precursors in young offspring of low-income families.
PUBDATE: 19790801
The revolutionary changes in the mores and practices of adolescent sexuality have not as yet resulted in a significant increase in the rates of cervical cancer precursors in a study of 29,600 young women under age 21. The study represents women from families of low socioeconomic status. Over a 21-year period no cases of carcinoma in situ nor of invasive cervix cancer occurred. The dysplasia rate was low (0.9/1000), and when prerevolutionary and revolutionary periods were compared, there were no significant differences in the rates. Cryocautery was successful in ablating dysplasia, as was follow-up without treatment. An attempt will be made to continue to monitor these young women of the sexual revolution since the effects of their past and current participation might not be discernible for years to come.


12. DOCID:5873 SCORE: 0.000540296905264733
DOCNO: 7023634
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Castration
QUALIFIER: therapy
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
AUTHOR: T Palshof T
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Canadian journal of surgery. Journal canadien de chirurgie.
COUNTRY: CANADA
TITLE: Symposium on the management of early breast cancer (stages I and II). Part II: Clinical experience with treatment methods. 5. Adjuvant endocrine therapy.
PUBDATE: 19810701
A number of trials of adjuvant therapy, including endocrine therapy, for primary breast cancer are in progress. There is an urgent need for increased international cooperation in study design, for defining stratification parameters and coordinating treatment strategy in future adjuvant trials of operable breast cancer. In this way the results of treatment in the different trials will be comparable. On the basis of encouraging clinical and experimental data, adjuvant endocrine therapy is expected to play a major role in the effort to improve the prognosis of primary breast cancer.


13. DOCID:7671 SCORE: 0.000516933815140378
DOCNO: 7363158
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Surgical Flaps
QUALIFIER: surgery
QUALIFIER: surgery
QUALIFIER: methods
AUTHOR: I B Rosen IB
AUTHOR: J A Palmer JA
AUTHOR: G A Knutson GA
PUBTYPE: Journal Article
JOURNALTITLE: Canadian journal of surgery. Journal canadien de chirurgie.
COUNTRY: CANADA
TITLE: Comparison of reconstructive methods used following ablative head and neck operations.
PUBDATE: 19800101
To overcome the sometimes crippling effect of extensive ablative surgery for oral cancer, two reconstructive techniques, the forehead flap of McGregor and the deltopectoral flap described by Bakamjian, have been incorporated into the operative procedure making it nearly routine. The records of 77 patients in whom 55 deltopectoral flaps and 30 forehead flaps were used were reviewed retrospectively. The failure rate of deltopectoral flaps was 16.4% and for forehead flaps was 7%. Causes of failure included infection, pressure by bone, prosthesis or teeth, residual cancer, previous irradiation and flap crowding. Functional results were similar with both flaps. The forehead flap is preferred although it has cosmetic disadvantages. Both these flap procedures, which are staged and result in prolonged hospitalization for the patient, may in the future be replaced by myocutaneous and free-flap reconstructions.


14. DOCID:6829 SCORE: 0.000512330168020668
DOCNO: 6166019
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Mastectomy
QUALIFIER: analysis
QUALIFIER: analysis
QUALIFIER: analysis
QUALIFIER: analysis
QUALIFIER: analysis
AUTHOR: A P Cipolloni AP
AUTHOR: P Collini P
AUTHOR: L Pierini L
AUTHOR: R Rossi R
AUTHOR: L Cenciotti L
PUBTYPE: Journal Article
JOURNALTITLE: Quaderni Sclavo di diagnostica clinica e di laboratorio.
COUNTRY: ITALY
TITLE: [Protein, immunological and "Gc", "Gm" and "Inv" picture in high-risk mastectomized subjects]
PUBDATE: 19800301
In the field of research on cancer we studied 294 women of which 142 who had undergone mastectomy, 70 selected for a high risk group, 82 normal. In order to determine some parameters who characterize the three groups we research for each the globulin factor Gc, Gm, and Inv, the proteic fractions and the immunoglobulins, as already pointed out by other investigators. The study of data points out results some times not according to previous reports. Comparing people who had undergone mastectomy and who had been selected for a high risk group, on the bases of GC phenotype together with immunoglobulins we obtained interesting values that characterize and delimit the two groups.